The following Stem Cell stocks will be higher today due to the decision from Barack Obama to overturn the block on government funding for embryonic stem cell research. White House officials said Sunday that the president's order will give the National Institutes of Health 120 days to develop ethical guidelines for the research.
Stem Cell Stocks March 9, 2009 - Pre Market
Stem Cells ( STEM ) - $2.21 Up 60.14%
Geron ( GERN ) - $5.10 Up 31.78%
Aastrom Biosciences ( ASTM ) - $0.63 Up 90.91%
Pluristem Therapeutics (PSTI) - $1.23 Up 15%
Opexa Theraputics ( OPXA ) - $0.55 Up 83.33%
Thermogenesis ( KOOL ) - $0.60 Up 49.25%
Cytori Therapeutics ( CYTX ) - $3.30 Up 42.86%
Today's Biggest Stock Market Gainers - Top 2009 Stock Gainers - Top 2009 Penny Stocks - Baltic Dry Index
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
Showing posts with label stem cells. Show all posts
Showing posts with label stem cells. Show all posts
Monday, March 9, 2009
Monday, January 26, 2009
Biggest Stock Gainers 1/26/09 - January 26, 2009
Today, January 26, 2009, their are several stocks gainers that are breaking out in the stock market despite the fact that we are approaching the lows for the day. Check out today's biggest gainers and the Top Stocks for 2009.
Hot Stocks 1/26/09 - Biggest Gainers Today
Barclays ( BCS ) - $4.92 Up 60.17% - Barclays stock surges after profit reassurance.
Allied Irish Banks ( AIB ) - $2.80 Up 35% - AIB is going up with the above Barclays news.
Ouiksilver ( ZQK ) - $2.07 Up 37.02% - Quiksilver stock is surging on speculation of a takeover by another company.
Geron ( GERN ) - $7.87 Up 11% - GERN continues to soar on the FDA Stem Cell News which was released Friday.
Stem Cells ( STEM ) - $2.69 Up 6.32% - STEM continues to soar on the above Geron news and is up 14 of the past 16 trading sessions. STEM has become an explosive stock and is one of 2009's Top Stock Gainers.
Other Stocks doing well - DRYS, ASTM, FCX, ING, GASS
For More Stock Market Updates, visit , http://daytradingstockblog.blogspot.com/ or Subscribe for FREE
Hot Stocks 1/26/09 - Biggest Gainers Today
Barclays ( BCS ) - $4.92 Up 60.17% - Barclays stock surges after profit reassurance.
Allied Irish Banks ( AIB ) - $2.80 Up 35% - AIB is going up with the above Barclays news.
Ouiksilver ( ZQK ) - $2.07 Up 37.02% - Quiksilver stock is surging on speculation of a takeover by another company.
Geron ( GERN ) - $7.87 Up 11% - GERN continues to soar on the FDA Stem Cell News which was released Friday.
Stem Cells ( STEM ) - $2.69 Up 6.32% - STEM continues to soar on the above Geron news and is up 14 of the past 16 trading sessions. STEM has become an explosive stock and is one of 2009's Top Stock Gainers.
Other Stocks doing well - DRYS, ASTM, FCX, ING, GASS
For More Stock Market Updates, visit , http://daytradingstockblog.blogspot.com/ or Subscribe for FREE
Friday, January 23, 2009
Biggest Stock Gainers 1/23/09 - January 23, 2009
Today, January 23, 2009, their are several stocks gainers that are breaking out in the stock market despite the weakness we are seeing in the major averages. Check out today's biggest gainers and the Top Stocks for 2009.
Hot Stocks 1/23/09 - Biggest Gainers
Geron ( GERN ) - $6.97 Up 33.78% - Geron received FDA Approval for the World's first clinical trial involving humans and Stem Cell Research. The CEO was on CNBC earlier in the day.
Stem Cells ( STEM ) - $2.63% Up 22% - Stem Cells is up on the above GERN news - Also up on this news is ASTM Aastom Biosciences. The Stem Cell Stocks are very hot today! We noted this yesterday!
Satyam ( SAY ) - $1.35 Up 26.16% - Satyam Board Announces Key Actions.
For More Stock Market Updates, visit , http://daytradingstockblog.blogspot.com/ or Subscribe for FREE
Hot Stocks 1/23/09 - Biggest Gainers
Geron ( GERN ) - $6.97 Up 33.78% - Geron received FDA Approval for the World's first clinical trial involving humans and Stem Cell Research. The CEO was on CNBC earlier in the day.
Stem Cells ( STEM ) - $2.63% Up 22% - Stem Cells is up on the above GERN news - Also up on this news is ASTM Aastom Biosciences. The Stem Cell Stocks are very hot today! We noted this yesterday!
Satyam ( SAY ) - $1.35 Up 26.16% - Satyam Board Announces Key Actions.
For More Stock Market Updates, visit , http://daytradingstockblog.blogspot.com/ or Subscribe for FREE
Geron GERN Stem Cell Stocks 1/23/09
Geron ( GERN ) is out with Stem Cell news this morning, January 23, 2009 - as this company will be the first company testing a human in the world's first human clinical trial involving Stem Cells. Under the new Obama administration, the FDA has approved this trial in which the Bush administration wasn't allowing Government funding for Stem Cell Research.
GERN stock is exploding higher today, to $6.48 Up 24%. Other Stem Cell stocks are higher such as Stem Cells ( STEM ) and Aastrom Biosciences ( ASTM )
Geron Corporation (Nasdaq: GERN) announced today that the U.S. Food and Drug Administration (FDA) has granted clearance of the company's Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury.
The clearance enables Geron to move forward with the world's first study of a human embryonic stem cell (hESC)-based therapy in man. Geron plans to initiate a Phase I multi-center trial that is designed to establish the safety of GRNOPC1 in patients with "complete" American Spinal Injury Association (ASIA) grade A subacute thoracic spinal cord injuries.
"The FDA's clearance of our GRNOPC1 IND is one of Geron's most significant accomplishments to date," said Thomas Okarma, Ph.D., M.D., Geron's president and CEO. "This marks the beginning of what is potentially a new chapter in medical therapeutics - one that reaches beyond pills to a new level of healing: the restoration of organ and tissue function achieved by the injection of healthy replacement cells. The ultimate goal for the use of GRNOPC1 is to achieve restoration of spinal cord function by the injection of hESC-derived oligodendrocyte progenitor cells directly into the lesion site of the patient's injured spinal cord."
GRNOPC1, Geron's lead hESC-based therapeutic candidate, contains hESC-derived oligodendrocyte progenitor cells that have demonstrated remyelinating and nerve growth stimulating properties leading to restoration of function in animal models of acute spinal cord injury (Journal of Neuroscience, Vol. 25, 2005).
"The neurosurgical community is very excited by this new approach to treating devastating spinal cord injury," said Richard Fessler, M.D., Ph.D., professor of neurological surgery at the Feinberg School of Medicine at Northwestern University. "Demyelination is central to the pathology of the injury, and its reversal by means of injecting oligodendrocyte progenitor cells would be revolutionary for the field. If safe and effective, the therapy would provide a viable treatment option for thousands of patients who suffer severe spinal cord injuries each year."
Full Article - http://www.geron.com/media/pressview.aspx?id=863
For More Stock Market Updates, visit , http://daytradingstockblog.blogspot.com/ or Subscribe for FREE
GERN stock is exploding higher today, to $6.48 Up 24%. Other Stem Cell stocks are higher such as Stem Cells ( STEM ) and Aastrom Biosciences ( ASTM )
Geron Corporation (Nasdaq: GERN) announced today that the U.S. Food and Drug Administration (FDA) has granted clearance of the company's Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury.
The clearance enables Geron to move forward with the world's first study of a human embryonic stem cell (hESC)-based therapy in man. Geron plans to initiate a Phase I multi-center trial that is designed to establish the safety of GRNOPC1 in patients with "complete" American Spinal Injury Association (ASIA) grade A subacute thoracic spinal cord injuries.
"The FDA's clearance of our GRNOPC1 IND is one of Geron's most significant accomplishments to date," said Thomas Okarma, Ph.D., M.D., Geron's president and CEO. "This marks the beginning of what is potentially a new chapter in medical therapeutics - one that reaches beyond pills to a new level of healing: the restoration of organ and tissue function achieved by the injection of healthy replacement cells. The ultimate goal for the use of GRNOPC1 is to achieve restoration of spinal cord function by the injection of hESC-derived oligodendrocyte progenitor cells directly into the lesion site of the patient's injured spinal cord."
GRNOPC1, Geron's lead hESC-based therapeutic candidate, contains hESC-derived oligodendrocyte progenitor cells that have demonstrated remyelinating and nerve growth stimulating properties leading to restoration of function in animal models of acute spinal cord injury (Journal of Neuroscience, Vol. 25, 2005).
"The neurosurgical community is very excited by this new approach to treating devastating spinal cord injury," said Richard Fessler, M.D., Ph.D., professor of neurological surgery at the Feinberg School of Medicine at Northwestern University. "Demyelination is central to the pathology of the injury, and its reversal by means of injecting oligodendrocyte progenitor cells would be revolutionary for the field. If safe and effective, the therapy would provide a viable treatment option for thousands of patients who suffer severe spinal cord injuries each year."
Full Article - http://www.geron.com/media/pressview.aspx?id=863
For More Stock Market Updates, visit , http://daytradingstockblog.blogspot.com/ or Subscribe for FREE
Thursday, December 18, 2008
Stem Cells STEM FDA Approval 12/18/08
Expect Stem Cells ( STEM ) to be a big gainer today, 12/18/08, as this company received FDA Approval to initiate a clinical trial of the Company’s proprietary HuCNS-SC product candidate (purified human neural stem cells) to treat Pelizaeus-Merzbacher Disease (PMD), a fatal brain disorder that mainly affects young children. This Phase I trial is designed to evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for PMD. Currently, there are no approved treatments for this disease.
This is the Company’s second FDA-approved clinical trial to evaluate HuCNS-SC cells as a potential treatment for neurodegenerative diseases. The first such study was the Company’s Phase I clinical trial of HuCNS-SC cells to treat neuronal ceroid lipofuscinoses (NCL), or Batten disease. The Phase I NCL trial will be completed in January 2009.
Patients with PMD are born with a gene mutation that results in insufficient myelination of nerve fibers in the brain, neurological impairment and eventually death. Myelin, which is produced by special cells called oligodendrocytes, insulates nerve fibers to allow electrical signals to be conducted normally. Other, more common, myelination diseases include cerebral palsy, transverse myelitis and multiple sclerosis
STEM is up 16% to $1.54 in pre market trading.
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
This is the Company’s second FDA-approved clinical trial to evaluate HuCNS-SC cells as a potential treatment for neurodegenerative diseases. The first such study was the Company’s Phase I clinical trial of HuCNS-SC cells to treat neuronal ceroid lipofuscinoses (NCL), or Batten disease. The Phase I NCL trial will be completed in January 2009.
Patients with PMD are born with a gene mutation that results in insufficient myelination of nerve fibers in the brain, neurological impairment and eventually death. Myelin, which is produced by special cells called oligodendrocytes, insulates nerve fibers to allow electrical signals to be conducted normally. Other, more common, myelination diseases include cerebral palsy, transverse myelitis and multiple sclerosis
STEM is up 16% to $1.54 in pre market trading.
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
Monday, November 10, 2008
Dow Jones Close 11/10/08 - Stock Market Report
Stock Market Closing Prices - 11/10/08
Dow Jones Industrial Average ( DJIA ) Close - 8870.54 Down 73
Nasdaq Stock Market Close - 1616.74 Down 30.66
S&P 500 Close - 919.28 Down 11.71
Libor Rates - 11/10/08
1 Month - 1.54%
3 Month - 2.24%
Commodities Closing Prices - 11/10/08
Gold - 725.30
Oil - 746.40
Natural Gas - 7.22
The Dow Jones Industrial Average closed at 8871 on 11/10/08, as investors dealt shook off a huge stimulus package from China and pushed stocks down for the day. The Stock Market Futures were up big this morning, The Dow Jones futures were actually up 250 at one point but the rally fizzled during the morning trading session and eventually pushed in to negative territory during the afternoon hours. General Motors ( GM ) was downgraded with a price target of Zero, Circuit City ( CC ) went bankrupt, Goldman Sachs ( GS ) continued its free fall, Googles ( GOOG ) price target was cut, and the was very light volume today. These were the reasons for the failed rally today adding to the fact that there was not much buy interest today. I suspect you could see more selling as we start the day Tuesday. A bright spot was AIG today as the stock went up 9% on their earnings results.
Biggest Gainers November 10th, 2008
One of the biggest gainers today was STEM, this stock hit a high of $2.48 per share before retracing all the way back to $2.10 before bouncing at the close. STEM had volume over 10 million shares today.
Another stock I will be watching is Las Vegas Sands ( LVS )....this company reports earnings today. You had a nice short squeeze this afternoon with heavy volume but we'll have to see what the company reports and says in their conference call. Keep an eye on this stock tomorrow.
For more updates on the stock market, visit, http://daytradingstockblog.blogspot.com/
Dow Jones Industrial Average ( DJIA ) Close - 8870.54 Down 73
Nasdaq Stock Market Close - 1616.74 Down 30.66
S&P 500 Close - 919.28 Down 11.71
Libor Rates - 11/10/08
1 Month - 1.54%
3 Month - 2.24%
Commodities Closing Prices - 11/10/08
Gold - 725.30
Oil - 746.40
Natural Gas - 7.22
The Dow Jones Industrial Average closed at 8871 on 11/10/08, as investors dealt shook off a huge stimulus package from China and pushed stocks down for the day. The Stock Market Futures were up big this morning, The Dow Jones futures were actually up 250 at one point but the rally fizzled during the morning trading session and eventually pushed in to negative territory during the afternoon hours. General Motors ( GM ) was downgraded with a price target of Zero, Circuit City ( CC ) went bankrupt, Goldman Sachs ( GS ) continued its free fall, Googles ( GOOG ) price target was cut, and the was very light volume today. These were the reasons for the failed rally today adding to the fact that there was not much buy interest today. I suspect you could see more selling as we start the day Tuesday. A bright spot was AIG today as the stock went up 9% on their earnings results.
Biggest Gainers November 10th, 2008
One of the biggest gainers today was STEM, this stock hit a high of $2.48 per share before retracing all the way back to $2.10 before bouncing at the close. STEM had volume over 10 million shares today.
Another stock I will be watching is Las Vegas Sands ( LVS )....this company reports earnings today. You had a nice short squeeze this afternoon with heavy volume but we'll have to see what the company reports and says in their conference call. Keep an eye on this stock tomorrow.
For more updates on the stock market, visit, http://daytradingstockblog.blogspot.com/
Subscribe to:
Posts (Atom)
